Home › Funds › PERCEPTIVE ADVISORS LLC › AMLX

PERCEPTIVE ADVISORS LLC position in AMLX

AMYLYX PHARMACEUTICALS INC · Health Care

PERCEPTIVE ADVISORS LLC reported holding 8,334,882 shares of AMLX (AMYLYX PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$149.7M, representing 2.37% of its reported portfolio and ranking #12 among its reported holdings. PERCEPTIVE ADVISORS LLC has disclosed AMLX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)8.33M sh
Reported value held$149.69M
Portfolio Weight2.37%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How PERCEPTIVE ADVISORS LLC's AMLX position evolved

PERCEPTIVE ADVISORS LLC first disclosed a stake in AMLX in Q3 2023 at 2,688,873 shares (US$49.2M). The position peaked in Q2 2026 at 8,334,882 shares, worth US$149.7M. Across 11 filings, PERCEPTIVE ADVISORS LLC increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 8,334,882 shares valued at US$149.7M — an increase of 50,000 shares quarter over quarter.. Notable position changes include a 30% trim in Q4 2023 (shares fell 81% over the following quarter), a 84% trim in Q1 2024 (shares fell 33% over the following quarter), a 219% increase in Q4 2024 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.69M $49.23M New
Q4 2023 1.87M $27.51M Reduce
Q1 2024 300.00K $852.00K Reduce
Q3 2024 2.13M $6.89M New
Q4 2024 6.77M $25.61M Add
Q1 2025 7.87M $27.88M Add
Q2 2025 7.90M $50.65M Hold
Q3 2025 8.95M $121.66M Add
Q4 2025 8.28M $100.08M Reduce
Q1 2026 8.28M $115.16M Hold
Q2 2026 8.33M $149.69M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMLX and 13F data

AMLX (AMYLYX PHARMACEUTICALS INC) is a Health Care company. 50 other funds we track also report a position in AMLX — the largest reported positions include TCG Crossover Management, LLC (US$112.1M), Commodore Capital LP (US$101.5M), Saturn V Capital Management LP (US$83.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMLX

All AMLX fund holders →

FAQ

How long has PERCEPTIVE ADVISORS LLC held AMLX?

PERCEPTIVE ADVISORS LLC has disclosed AMLX holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is PERCEPTIVE ADVISORS LLC's current position in AMLX?

As of Q2 2026, PERCEPTIVE ADVISORS LLC holds 8.33M shares of AMLX (AMYLYX PHARMACEUTICALS INC), valued at $149.69M, representing 2.37% of its reported portfolio and ranking #12.

Has PERCEPTIVE ADVISORS LLC been buying or selling AMLX?

In the latest 13F filing (Q2 2026), PERCEPTIVE ADVISORS LLC increased its position in AMLX. The position peaked in Q2 2026 at 8.33M shares.

Which other funds hold AMLX?

Other major institutional holders of AMLX include TCG Crossover Management, LLC, Commodore Capital LP, Saturn V Capital Management LP, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.